๐Ÿšจ Everything is back in stock โ€” all peptides available now ๐Ÿšจ
Shop/Recovery & Resilience
Recovery & Resilience

Wolverine Blend ยท 20 mg

The two most-used repair peptides, co-lyophilised at the factory into one vial. BPC-157 works where you inject it; TB-500 travels. One injection a day covers both โ€” at a ratio you can't change.

Read the research on Wolverine and other blends
Lab-verified ยท Same-day Bali delivery ยท Pay on delivery
Format
Total
Rpย 2.100.000
1

Includes 10ร— sterile insulin syringes + 1 vial of bacteriostatic water, free with your order.

Complete your kit

Insulin Syringes
Insulin Syringes
1 unit
Rpย 7.000
Alcohol Prep Swabs
Alcohol Prep Swabs
1 unit
Rpย 1.000
BAC Water (Bacteriostatic Water)
BAC Water (Bacteriostatic Water)
10 ml
Rpย 125.000
Insulated Travel Case
Insulated Travel Case
Hard case
Rpย 150.000
AVERON Peptide Pen โ€” V2 Aluminium
AVERON Peptide Pen โ€” V2 Aluminium
Colour: Black
Rpย 950.000

For research and educational use only. Not for human or veterinary consumption.

What people consistently report:

  • Less pain around tendons, ligaments and old strains โ€” usually the first thing noticed, most often somewhere in weeks 2โ€“4
  • Mobility and range of motion coming back, the effect most often credited to the TB-500 half
  • Better recovery between hard sessions for people training around a niggle
  • Gut relief from the BPC-157 half โ€” reflux and irritated-gut symptoms. If your gut is the main reason, BP-157 alone or our Gut & Immunity package fits better; TB-500 adds nothing specific there.
  • One daily injection instead of two โ€” the practical reason this blend exists

Why these two are stacked

BPC-157 is the local one: in animal and cell studies it drives new blood vessels into damaged tissue and helps tendon cells survive and migrate. TB-500 is the actin-binding fragment of thymosin beta-4 โ€” the protein cells use to move into a wound โ€” and it acts throughout the body. Blood supply plus cell movement is the logic of the stack.

It is a logic, not a result. No controlled study has ever tested the two together.

No human trial has shown this blend heals anything. The only published human data on the pair is a 2021 chart review in which 4 knee-pain patients received both by injection into the joint โ€” 3 reported relief. No control group, no imaging. The first properly controlled BPC-157 trial (hamstring strains, 120 people) is still recruiting.

It does not fix a complete tear, a full rupture, or a labral lesion. Those need a surgical opinion.

It does not mean you're healed when the pain stops. This is the one that actually injures people. Pain settling is not tissue repaired. Tendon remodels over months; your physio decides when load goes back on, not how the joint feels in week three.

It is not adjustable. The 1:1 ratio is fixed โ€” you cannot raise the TB-500 without raising the BPC-157 with it.

Common: injection site reactions โ€” redness, small lumps, temporary soreness. Rotate sites.

Less common: a head rush, lightheadedness or tiredness shortly after injecting, reported mostly with TB-500. Mild nausea or headache in the first days.

Theoretical concern: both compounds promote blood-vessel growth. Whether that could feed an existing, undiagnosed tumour is unknown โ€” there is no human data either way. That's why we say not to use this with active cancer or a recent cancer history.

Unknown: the long-term human safety of either peptide, alone or together, is genuinely uncharacterised.

Stop and see a doctor:

  • Spreading redness, heat, pus or fever around an injection site โ€” possible infection
  • Hives, swelling of the face or lips, or difficulty breathing
  • Chest pain, a racing heart, or fainting

Do not use if you are pregnant or breastfeeding, under 18, or have active or recent cancer. On blood thinners? Talk to your doctor first.

Draw past the line, tap out bubbles, push back to the line.

The AVERON Peptide Pen delivers 1 click = 0.01 mL. A U-100 insulin syringe delivers 1 unit = 0.01 mL. They are the same number. 20 clicks on the pen and 20 units on a syringe deliver exactly the same dose.

Maximum per injection: 100 units (1 mL)

20 mg vial + 2 mL bacteriostatic water = 10 mg/mL total โ€” 5 mg/mL of each

Units (U-100)VolumeDelivers (label)This batch (lab-tested)
50.05 mLBPC-157 250 mcg + TB-500 250 mcg317 mcg + 286 mcg
100.10 mLBPC-157 500 mcg + TB-500 500 mcg634 mcg + 571 mcg
200.20 mLBPC-157 1 mg + TB-500 1 mg1.27 mg + 1.14 mg

โš ๏ธ Do the maths on 10 mg, not 20. The most common mistake with this vial is treating it as "20 mg of one thing". Each draw contains equal labelled amounts of both โ€” 10 clicks is 500 mcg of each, 1 mg in total.

About the lab report: the batch in stock tested at 12.68 mg BPC-157 and 11.42 mg TB-500 โ€” a slight overfill, about 27% and 14% above label. Every click delivers a little more than the label numbers, and slightly more BPC-157 than TB-500 (about 1.1 : 1). We publish click counts on the label amounts, which makes them the floor, not the ceiling.

Inject the water slowly down the inside wall of the vial. Swirl gently, never shake. It should be clear and colourless, with no particles.

Draw past the line, tap out bubbles, push back to the line.

The AVERON Peptide Pen delivers 1 click = 0.01 mL. A U-100 insulin syringe delivers 1 unit = 0.01 mL. They are the same number. 20 clicks on the pen and 20 units on a syringe deliver exactly the same dose.

Maximum per injection: 100 units (1 mL)

10 clicks (500 mcg of each), once daily, subcutaneous. Inject as close to the problem area as is practical โ€” the BPC-157 half seems to work best locally, and the TB-500 half reaches the rest of the body either way. For gut issues, abdomen.

WeeksUnits (U-100)FrequencyTB-500 per week
1โ€“410Daily3.5 mg
5โ€“8 (to 12 if chronic)105 days on, 2 off2.5 mg

Cycle: 8 weeks for most soft-tissue injuries, up to 12 for something chronic, then at least 4 weeks off.

The arithmetic: each vial is 20 draws of 10 clicks. That's 20 days at daily dosing, or exactly 4 weeks at 5 days a week โ€” so the 4-week refrigerated window never costs you anything. 8 weeks = 48 draws = 3 vials. 12 weeks = 68 draws = 4 vials. Each draw uses one syringe and the box includes 10, so add a syringe pack or use the pen.

Some people split the 10 clicks into 5 morning and 5 evening because BPC-157 is short-lived in the body. It uses the vial at the same rate. Going higher than 10 clicks is common online; there's no evidence it works better, and it doubles your cost.

Blend or separate vials?

Wolverine BlendBP-157 + TB-5 separately
Injections per dayOneOne or two
RatioFixed 1:1You choose
TB-500 loading at 5 mg/weekOnly by also taking 5 mg/week of BPC-157Yes โ€” 2.5 mg twice weekly
Best forOne simple daily habitFull control, one specific stubborn tendon

The honest trade-off: the standard separate protocol runs TB-500 at 2.5 mg twice weekly while BPC-157 stays at 500 mcg a day. This blend gives you 3.5 mg of TB-500 a week during loading โ€” lower โ€” and you can't change that without changing both. Experienced users chasing one specific injury often prefer separate vials. People who want one injection and nothing to calculate prefer this.

GLOW and KLOW contain these same two peptides plus GHK-Cu (and KPV in KLOW), but at their standard 10 clicks they deliver 333 mcg of each repair peptide, not 500. If repair is the only goal, this blend gives you more of it, with no copper and no sting.

  • 1ร— Wolverine Blend ยท 20 mg
  • 10ร— sterile insulin syringes (free)
  • 1ร— bacteriostatic water vial (free)
  • Compound Guide โ€” printed, included free

Both components rest on animal and cell data, with almost no human data. A 2025 systematic review of BPC-157 in orthopaedic sports medicine found 36 studies โ€” 35 preclinical, and one small uncontrolled human series. TB-500 itself has no human trials; the serious human thymosin beta-4 work is a separate eye-drop program. No trial has tested the two together. The first randomised, placebo-controlled BPC-157 trial (acute hamstring strain, 120 participants) started in 2026 and has not reported.

Regulatory: not approved anywhere. In the US, the FDA took BPC-157 and TB-500 off its 503A Category 2 safety-concern list in April 2026 after their compounding nominations were withdrawn. In July 2026 an FDA advisory committee voted 8โ€“6 to recommend both for compounding, against the advice of FDA staff, and in late October 2026 HHS published a draft policy tolerating pharmacy compounding of single-ingredient versions on prescription. None of that is an approval, and blends are excluded. What we supply is research-grade material.

Athletes: BPC-157 is named under WADA S0 and TB-500 under S2 (growth factors). Prohibited at all times.

Every peptide batch we sell is tested by Janoshik Analytical, an independent laboratory. Every vial carries an internal AVERON batch code identifying the lot received; each lot is linked to its published Janoshik report. The report carries the manufacturer's submission/task number, not the AVERON code. Ask us or our driver which report covers your code and open it on the laboratory's own website before paying. In our own-driver zone, the team shows you the vial and the report for that batch before payment.

A lab report handed to you by a seller and a lab report you can verify yourself are not the same thing. That's why we publish ours.

View COA on Janoshik
See also

More in Recovery & Resilience

...